Fairvalue-Calculator Fairvalue-Calculator
EN DE

Santen Pharmaceutical Co (SNPHY) Fair Value & Analysis

Healthcare · US · Market cap $3.9B

Price$12.31
Fair Value$16.78
Upside+36.3%
Quality96/100
Evidence: High Range $11.29 – $21.00

Analysis

Santen Pharmaceutical Co (SNPHY) currently trades at $12.31, while our model-based Fair Value estimate is $16.78 — implying the stock looks roughly 36.3% undervalued today. We read business quality at 96/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative filed for marketing approval for the treatment of glaucoma and ocular hypertension; and epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval to treat allergic conjunctivitis. The company also offers netarsudil mesylate/latanoprost, a fixed dose combination drug of a ROCK inhibitor and a prostaglandin F2a derivative which is in phase III clinical trial for the treatment of glaucoma and ocu…

Open the full interactive analysis →

Similar stocks

Eli Lilly and Company (LLY) -64% Johnson & Johnson, (JNJ) -47% AbbVie Inc (ABBV) -71% Roche Holding (ROGN) -96% Merck & Co (MRK) +7% AstraZeneca PLC (A1ZN34) -84%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.